



WITHDRAWN: Balancing the genetic risk of APOL1 kidney disease variants

Nongodo Firmin Kaboré, Sophie Limou

► To cite this version:

Nongodo Firmin Kaboré, Sophie Limou. WITHDRAWN: Balancing the genetic risk of APOL1 kidney disease variants. *Néphrologie & Thérapeutique*, 2019, 15, pp.S79-S84. 10.1016/j.nephro.2019.03.007 . inserm-02491391

HAL Id: inserm-02491391

<https://inserm.hal.science/inserm-02491391>

Submitted on 22 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Dochead: APO-L1/APO-L2

Balancing the genetic risk of *APOL1* kidney disease variants

Variations génétiques d'APOL1 et pathologies rénales associées

Nongodo Firmin Kaboré ^a, Sophie Limou ^{b*,c,d,e}

^a Department of Clinical Research, Centre MURAZ, Avenue de la liberté, Bobo-Dioulasso, Burkina Faso

^b Université de Nantes, UMR1064, 30, boulevard Jean-Monnet, 44093 Nantes cedex 1, France

^c Inserm, Centre de recherche en transplantation et immunologie (CRTI) UMR1064, 30, boulevard Jean-Monnet, 44093 Nantes cedex 1, France

^d Institut de transplantation en urologie-néphrologie (Itun), CHU de Nantes, 30, boulevard Jean-Monnet, 44093 Nantes cedex 1, France

^e École centrale de Nantes, 1 rue de la Noë, 44300 Nantes, France

*Corresponding author: Sophie Limou, PhD ; tel.: +33 244 768 271 ; e-mail: sophie.limou@univ-nantes.fr

Conflict of interests

None to declare.

1. Introduction

The 2012 Kidney Disease Outcomes Quality Initiative (KDOQI) defined chronic kidney disease as the persistence for more than 3 months of kidney damage (including albuminuria, imaging or histology-detected abnormalities) or kidney function impairment (characterized by a glomerular filtration rate below 60 ml/min/1.73m²) (1). Chronic kidney disease severity is classified into five stages (from G1 to G5) based on glomerular filtration rates and albuminuria range (1,2). Progression to stage G5 is known as end-stage kidney disease and is defined as kidney failure requiring renal replacement therapy (dialysis or kidney transplantation).

Chronic kidney disease represents a major and growing public health burden worldwide with 2 million deaths and 51 million disability-adjusted life-years (DALY) attributed to the disease in 2015 (3). Chronic kidney disease prevalence is estimated around 10 to 15% globally, and varies across populations with 3.3 to 17.3% reported in Europe, 14.8% in the United States of America (USA), 10.8% in China, and 5-17% in sub-Saharan Africa (4-9). In France, approximately 6 million people (10%) live with chronic kidney disease and 83,000 patients were treated for end-stage kidney disease in 2015 (10). The incidence rate for end-stage kidney disease increases every year by 2% and was of 166 per million inhabitants in France in 2015, which represents one of the highest values in Europe (mean incidence=119pmp) (10). Managing chronic kidney disease and its related complications has a considerable economic impact, with 3.4 billion euros spent in 2017 and more than 5 billion euros of projected costs for 2025 by the French national health insurance (CNAMTS) for end-stage kidney disease management alone (10,11).

The USA are even more affected by chronic and end-stage kidney disease, with an incidence of the latter of 378pmp and up to 7.2% of Medicare costs dedicated to its management (12). The total health insurance expenditure for chronic and end-stage kidney disease management exceeded \$98 billion in 2015 only (13). These high numbers notably conceal a major health disparity in kidney diseases with an increased risk for the African-American population, even after controlling for social economic status, life-style and other confounding factors (14,15). African-Americans are overall 3.5 times more likely to develop end-stage kidney disease than their counterparts of European ancestry. When discriminating by aetiology, African-Americans are more at risk for developing end-stage kidney disease for every major cause: diabetes, hypertension and glomerulopathies (12). These observations and the clustering of chronic and end-stage kidney disease among families supported the existence of genetic risk factors causing kidney diseases in African Americans (16,17).

Most of the increased risk for chronic kidney disease in African-Americans has been attributed to two genetic variants in the *APOL1* gene, named G1 and G2. This review summarizes the discovery

of *APOL1* renal risk alleles, the evolutionary arms race with trypanosomes, and the clinical applications for kidney transplantation.

2. Discovery of *APOL1* renal risk variants

Considering the overt disparity for chronic kidney disease in African-Americans, two groups implemented a mapping by admixture linkage disequilibrium strategy to identify the genetic determinants for this racial disparity in the recently admixed African-American population (18,19). The first group focused on non-diabetic end-stage kidney disease, when the second investigated two glomerulopathies, focal segmental glomerulosclerosis and human immunodeficiency virus (HIV)-associated nephropathy (or collapsing focal segmental glomerulosclerosis). Indeed, African-Americans are four to five times more likely to develop focal segmental glomerulosclerosis and have more than 18 times higher risk for developing HIV-associated nephropathy than European Americans (20,21). Using ancestry-informative markers spread across the genome, mapping by admixture linkage disequilibrium can differentiate chromosome portions originating from European or African ancestry in African-American individuals. By scrutinizing the genomes of an African-American population affected with kidney disease, mapping by admixture linkage disequilibrium can therefore map the genetic loci with increased African ancestry, that are likely associated with kidney disease. Both groups identified a strong association on chromosome 22 in a locus encompassing more than 30 different genes and centred on the *MYH9* gene.

The culprit gene was discovered two years later with the advent of the 1000 Genomes Project in the vicinity of *MYH9*. Two common coding genetic variants in the *APOL1* gene (G1 and G2) exhibited even stronger associations with focal segmental glomerulosclerosis and non-diabetic end-stage kidney disease than previously described (22,23). G1 corresponds to the rs73885319 nonsynonymous coding variant (p.S342G, NM_003661.3, 23% in the African-American population), and G2 is the rs71785313 two amino acid deletion (p.delN388/Y389, NM_003661.3, 13% in the African-American population). These two alleles appeared independently on opposing chromosomes and have never undergone genetic recombination, hence no haplotype carries simultaneously G1 and G2. The association with renal pathologies follows a recessive inheritance model (24): only African-Americans carrying two renal risk alleles (G1/G1 homozygous, G2/G2 homozygous and G1/G2 compound heterozygous, also known as the high-risk genotypes) have an increased risk for chronic kidney disease (**Figure 1a**). Approximately 14% of the African-American population carries two *APOL1* risk variants.

APOL1 associations with focal segmental glomerulosclerosis (OR 17) and HIV-associated nephropathy (OR 29) represent the strongest associations ever reported for common variants with a complex disease (25). Beyond focal segmental glomerulosclerosis/HIV-associated nephropathy, *APOL1* high-risk was further associated with numerous non-diabetic kidney phenotypes: hypertension-attributed end-stage kidney disease, sickle-cell nephropathy, lupus nephritis,

microalbuminuria and faster kidney function decline (22, 26-29). Finally, although no association was reported with the onset of the diabetic nephropathy, *APOL1* high-risk was associated with a more rapid kidney function decline in African Americans with diabetes (29).

3. Geographic distribution of *APOL1* variants and recent selective pressure

APOL1 renal risk variants have only been reported on African-derived chromosomes from the Americas (USA African-Americans, Afro-Caribbeans, Central Americans, Brazilians from Salvador) and Africa (24,30). G1 and G2 alleles are widely spread across sub-Saharan Africa, and reach very high frequencies in West Africa (over 40% for G1 and over 20% for G2) (24,30).

APOL1 G1 and G2 deleterious variants reached such high frequencies in West Africa due to recent positive selection events (22,31). It is believed that a coevolutionary arms race occurred between *APOL1* and African trypanosomes. *Trypanosoma brucei* are parasites transmitted by the tsetse fly that cause African sleeping sickness or trypanosomiasis. The *T.b. rhodesiense* subspecies is responsible for the acute form of the disease and restricted to Eastern and Southern Africa, whereas the *T.b. gambiense* subspecies is responsible for the chronic form of the disease in Western and Central Africa (32). *APOL1* is known as the human trypanolytic factor that can kill *T.b. brucei*, but *T.b. rhodesiense* and *T.b. gambiense* have evolved resistance mechanisms against *APOL1* lysis (33,34). Both G1 and G2 can restore in vitro *APOL1* trypanolytic activity against *T.b. rhodesiense* (**Figure 1b**) but have no impact on *T.b. gambiense* lysis (22,31). Interestingly, G2 was recently associated with a five times decreased risk of *T.b. rhodesiense* infection in a Uganda population (n=184 *T.b.r* infected vs. 180 controls) and G1 was associated with a protection against *T.b. gambiense* severity (OR 3) in Guineans (n=167 *T.b.g* clinical stage vs. 60 *T.b.g* asymptomatic carriers) (35). These reports clearly establish a role for *APOL1* G1 and G2 variants in the fight against African trypanosomiasis, and illustrate a perfect example of balancing selection between chronic kidney disease risk and trypanosomiasis protection (**Figure 1**).

However, the evolution story of *APOL1* variants seems to be more complex than described above. There is indeed a geographic paradox between G2 high frequency in West Africa and *T.b. rhodesiense* distribution in Eastern and Southern Africa (24,35,36). One hypothesis is that *T.b. rhodesiense* was the driving positive selection force for G2, and that its endemicity would have shifted toward East due to the rising G2 frequency or due to an environmental pressure. However, there is very little epidemiological data supporting this theory to date. In addition, G2 was found to confer an increased risk to *T.b. gambiense* severity (OR 3) in Guineans (35), which might seem in contradiction with the current West Africa endemicity of *T.b. gambiense*. An alternate hypothesis to explain this puzzle is that another pathogen would have driven G2 selection in West Africa. This model is supported by several piece of evidence indicating that *APOL1* might play a broader innate immunity role against infections (37–39).

4. APOL1 cellular function

The mechanisms leading to APOL1 resistance against *T. brucei* infections have been largely studied. Briefly, APOL1 circulates in the bloodstream as a component of high density lipoproteins. Upon receptor-mediated endocytosis, the progressive acidification of the endolysosomal compartment triggers a conformational change that drives APOL1 to the lysosomal membrane where it forms a pore provoking the parasite lysis (40,41). To counteract APOL1 trypanolytic activity, both *T.b.* subspecies have evolved independent mechanisms to prevent APOL1 lethal membrane insertion: *T.b. rhodesiense* acquired a SRA glycoprotein that directly interacts with APOL1 C-terminal region, whereas *T.b. gambiense*-specific glycoprotein (TgsGP) stiffens the endolysosomal parasitic membrane (33,34).

Beyond its trypanolytic activity, APOL1 plays a broader protective role in innate immunity. It is upregulated by proinflammatory cytokines including interferon γ and tumour necrosis factor α , protects against Leishmania parasitic infection, and restricts HIV in vitro replication (37-39,42,43).

The investigation of APOL1 cellular function has been hampered by its high level of associated cytotoxicity (44,42,45), and the lack of proper animal models. APOL1 is a member of the APOL family (APOL1-6) that arose by gene duplications in primates only. *APOL* homologs are found throughout the animal kingdom, but only humans, gorillas and baboons retained a functional *APOL1* gene, which suggest that the fitness cost is greater than the innate immunity benefit, and that APOL1 is not necessary for kidney development or normal function (46–48).

Most reports investigating APOL1 renal function are therefore based on cell models, but recently some transgenic mouse models were successfully established (36). Numerous mechanisms have been proposed to explain APOL1-induced kidney injury, and the identification of the clinically relevant pathway(s) is yet to be confirmed. First, APOL1 renal risk variants were shown to impair mitochondrial function in cell models (49,50). Second, autophagy and an alteration of vesicle trafficking were proven as major actors of APOL1-mediated cell death mechanism, both in cell and animal models (51–54). Interestingly, the mouse model developed by Beckerman et al. successfully recapitulates proteinuria, podocyte effacement, and the molecular signature of human APOL1-related kidney disease (54). Third, the soluble urokinase plasminogen activator receptor (suPAR) was reported to form a complex with APOL1 and $\alpha_v\beta_3$ integrin on mouse podocytes causing proteinuria in a suPAR-dependent manner (55). Similarly, suPAR levels were shown to modulate APOL1-related renal risk in two independent cohorts, but the implication of suPAR in chronic kidney disease remains controversial (55,56). Finally, a surprising role for *APOL1* RNA was recently associated with podocyte damage through the activation of protein kinase R (PKR) in cells and transgenic mice (57).

Further studies will be necessary to discriminate the pathway(s) relevant for drug targeting. Ultimately, any molecular mechanism proposed for APOL1-driven kidney injury will have to (i) reconcile with the strong recessive pattern of inheritance observed in every epidemiological study, and

(ii) account for the fact that the majority of African-Americans carrying *APOL1* high-risk (14% of African-Americans) do not develop chronic kidney disease, suggesting the intervention of a second factor (58).

5. *APOL1* and clinical translation – the kidney transplantation case

Shortly after the discovery of *APOL1* renal risk variants, several groups became interested in their potential impact on kidney allograft survival. If allograft survival is not affected by the recipient *APOL1* genotype, the donor *APOL1* high-risk genotype was significantly associated with shorter survival in three independent studies involving deceased donors (HR ~2) (59–62) (**Figure 2**). In addition, *APOL1* high-risk was associated with an increased risk for postnephrectomy end-stage kidney disease in living kidney donors (63,64).

These observations raise the question of systematic *APOL1* genotyping in potential African-American kidney donors (deceased or living). *APOL1* genotyping could contribute to upgrade donor-recipient matching to extend allograft survival and limit adverse kidney transplantation outcomes. *APOL1* genotyping could also be beneficial for potential living kidney donors with African ancestry by assessing their future risk for end-stage kidney disease.

A recent study rose hope in potential positive impact of *APOL1* genotyping for kidney transplantation outcomes (65). Before the identification of *APOL1* renal risk variants, racial disparities had been observed in kidney transplantation outcomes: allografts from African-American donors exhibit a shorter survival compared to organs donated by European Americans. Race was therefore one of the ten donor characteristics (along with age, body mass index, history of diabetes or hypertension, etc.) included in the kidney donor risk index that quantifies risk for allograft failure and enhances graft allocation from deceased donors (66). The kidney donor risk index assigns the same negative weight to all African-American donors, whether they carry the *APOL1* high-risk genotype or not. Very interestingly, one group demonstrated that replacing donor race with *APOL1* genotype was improving the predictive power of the kidney donor risk index and graft allocation, while increasing the pool of potential functioning organs (65).

Beyond this study, very few data support a clinical benefit for *APOL1* genotyping. The National Institutes of Health (NIH) initiated the *APOL1* long-term kidney transplantation outcomes (APOLLO) network to provide prospective, objective and critical information on potential benefits and ethical considerations for genotyping African-American donors (67). This project has the potential to (i) provide revised policies on donor-recipient matching, with positive consequences on prolonged allograft survival and reduced organ discard, and (ii) provide critical safety data for potential living kidney donors regarding postdonation end-stage kidney disease risk.

6. Conclusion

The identification of *APOL1* renal risk variants has been a major discovery for the nephrology community in understanding most of the excess risk for non-diabetic chronic kidney disease in African-Americans. In less than 10 years, data have immensely mounted up on the *APOL1* gene and cellular function. *APOL1* is a perfect example of balancing selection between the chronic kidney disease susceptibility of high-risk carriers and the positive selection for resistance against trypanosome infections, even if the evolutive story might be more complex than anticipated. Investigating further cellular and animal models will be necessary to decipher the precise molecular mechanisms of *APOL1*-induced kidney injury and will be an essential step toward developing new therapeutic strategies. Finally, the community has hope to soon leverage *APOL1* genotyping for improving the management of kidney transplantation and living donation, as a promise of personalized medicine approach.

Author contribution

NFK and SL have compiled the literature and cowritten this review. SL realized the figures.

References

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39(2 Suppl 1):S1-266.
2. Anon. Chapter 1: Definition and classification of CKD. *Kidney Int Suppl* 2013;3(1):19–62.
3. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016 8;388(10053):1459–544.
4. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013;382(9888):260–72.
5. Levin A, Tonelli M, Bonventre J, Coresh J, Donner J-A, Fogo AB, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. *Lancet* 2017 21;390(10105):1888–917.
6. Brück K, Stel VS, Gambaro G, Hallan S, Völzke H, Ärnlöv J, et al. CKD prevalence varies across the european general population. *J Am Soc Nephrol* 2016;27(7):2135–47.
7. Anon. Chapter 1: CKD in the General Population. *Am J Kidney Dis* 2018;71(3):S9–30.
8. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. *Lancet* 2012;379(9818):815–22.

9. Stanifer JW, Muir A, Jafar TH, Patel UD. Chronic kidney disease in low- and middle-income countries. *Nephrol Dial Transplant* 2016;31(6):868–74.
10. Le Neindre C, Bricard D, Sermet C, Bayer F, Couchoud C, Lassalle M. Atlas de l'insuffisance rénale chronique terminale en France. Paris: Institut de recherche et documentation en économie de la santé (Irdes); 2018. Available online at: <http://www.irdes.fr/recherche/ouvrages/004-atlas-de-l-insuffisance-renale-chronique-terminale-en-france.pdf>
11. Anon. Le rapport médical et scientifique du prélèvement et de la greffe rénale en France - 2015. Saint-Denis: Agence de la Biomédecine 2015. Available online at: <https://www.agence-biomedecine.fr/annexes/bilan2015/donnees/organes/06-rein/synthese.htm>
12. Saran R, Robinson B, Abbott KC, Agodoa LYC, Albertus P, Ayanian J, et al. US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States. *Am J Kidney Dis* 2017;69(3)(suppl 1):S1-S688.
13. Anon. Chapter 9: Healthcare expenditures for persons with ESRD. *Am J Kidney Dis* 2018;71(3):S433–40.
14. Anon. Chapter 1: Incidence, prevalence, patient characteristics, and treatment modalities. *Am J Kidney Dis* 2018;71(3):S247–76.
15. Derose SF, Rutkowski MP, Crooks PW, Shi JM, Wang JQ, Kalantar-Zadeh K, et al. Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system. *Am J Kidney Dis* 2013;62(2):236–44.
16. Freedman BI, Volkova NV, Satko SG, Krisher J, Jurkovitz C, Soucie JM, et al. Population-based screening for family history of end-stage renal disease among incident dialysis patients. *Am J Nephrol* 2005;25(6):529–35.
17. Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. *Am J Kidney Dis* 1999;34(2):254–8.
18. Kao WHL, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. *Nat Genet* 2008;40(10):1185–92.
19. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. *Nat Genet* 2008;40(10):1175–84.
20. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. *Am J Kidney Dis* 2004;44(5):815–25.

21. Kopp JB, Winkler C. HIV-associated nephropathy in African Americans. *Kidney Int Suppl* 2003;(83):S43-49.
22. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. *Science* 2010 13;329(5993):841–5.
23. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, et al. Missense mutations in the *APOL1* gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. *Hum Genet* 2010;128(3):345–50.
24. Limou S, Nelson GW, Kopp JB, Winkler CA. *APOL1* kidney risk alleles: population genetics and disease associations. *Adv Chronic Kidney Dis* 2014;21(5):426–33.
25. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. *APOL1* genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. *J Am Soc Nephrol* 2011;22(11):2129–37.
26. Ashley-Koch AE, Okocha EC, Garrett ME, Soldano K, De Castro LM, Jonassaint JC, et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. *Br J Haematol* 2011;155(3):386–94.
27. Larsen CP, Beggs ML, Saeed M, Walker PD. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. *J Am Soc Nephrol* 2013;24(5):722–5.
28. Peralta CA, Bibbins-Domingo K, Vittinghoff E, Lin F, Fornage M, Kopp JB, et al. *APOL1* genotype and race differences in incident albuminuria and renal function decline. *J Am Soc Nephrol* 2016;27(3):887–93.
29. Parsa A, Kao WHL, Xie D, Astor BC, Li M, Hsu C, et al. *APOL1* risk variants, race, and progression of chronic kidney disease. *N Engl J Med* 2013;369(23):2183–96.
30. Nadkarni GN, Gignoux CR, Sorokin EP, Daya M, Rahman R, Barnes KC, et al. Worldwide frequencies of *APOL1* renal risk variants. *N Engl J Med* 2018 27;379(26):2571–2.
31. Limou S, Nelson GW, Lecordier L, An P, O’huigin CS, David VA, et al. Sequencing rare and common *APOL1* coding variants to determine kidney disease risk. *Kidney Int* 2015;88(4):754–63.
32. Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. *Lancet* 2017;390(10110):2397–409.

33. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. *Nature* 2003;422(6927):83–7.
34. Uzureau P, Uzureau S, Lecordier L, Fontaine F, Tebabi P, Homblé F, et al. Mechanism of *Trypanosoma brucei gambiense* resistance to human serum. *Nature* 2013;501(7467):430–4.
35. Cooper A, Ilboudo H, Alibu VP, Ravel S, Enyaru J, Weir W, et al. *APOL1* renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. *eLife* 2017;6:e25461.
36. Freedman BI, Limou S, Ma L, Kopp JB. APOL1-associated nephropathy: a key contributor to racial disparities in CKD. *Am J Kidney Dis* 2018;72(5S1):S8–16.
37. Samanovic M, Molina-Portela MP, Chessler A-DC, Burleigh BA, Raper J. Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates Leishmania infection. *PLoS Pathog* 2009;5(1):e1000276.
38. Taylor HE, Khatua AK, Popik W. The innate immune factor apolipoprotein L1 restricts HIV-1 infection. *J Virol* 2014;88(1):592–603.
39. McLaren PJ, Gawanbacht A, Pyndiah N, Krapp C, Hotter D, Kluge SF, et al. Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses. *Retrovirology* 2015;12:41.
40. Pérez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homblé F, et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. *Science* 2005;309(5733):469–72.
41. Molina-Portela M del P, Lugli EB, Recio-Pinto E, Raper J. Trypanosome lytic factor, a subclass of high-density lipoprotein, forms cation-selective pores in membranes. *Mol Biochem Parasitol* 2005;144(2):218–26.
42. Nichols B, Jog P, Lee JH, Blackler D, Wilmot M, D’Agati V, et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. *Kidney Int* 2015;87(2):332–42.
43. Horrevoets AJ, Fontijn RD, van Zonneveld AJ, de Vries CJ, ten Cate JW, Pannekoek H. Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. *Blood* 1999;93(10):3418–31.

44. Lan X, Jhaveri A, Cheng K, Wen H, Saleem MA, Mathieson PW, et al. *APOL1* risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. *Am J Physiol Renal Physiol* 2014;307(3):F326-336.
45. Olabisi OA, Zhang J-Y, VerPlank L, Zahler N, DiBartolo S, Heneghan JF, et al. *APOL1* kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. *Proc Natl Acad Sci U S A* 2016;113(4):830-7.
46. Smith EE, Malik HS. The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. *Genome Res* 2009;19(5):850-8.
47. Poelvoorde P, Vanhamme L, Van Den Abbeele J, Switzer WM, Pays E. Distribution of apolipoprotein L-I and trypanosome lytic activity among primate sera. *Mol Biochem Parasitol* 2004;134(1):155-7.
48. Thomson R, Molina-Portela P, Mott H, Carrington M, Raper J. Hydrodynamic gene delivery of baboon trypanosome lytic factor eliminates both animal and human-infective African trypanosomes. *Proc Natl Acad Sci U S A* 2009;106(46):19509-14.
49. Ma L, Chou JW, Snipes JA, Bharadwaj MS, Craddock AL, Cheng D, et al. *APOL1* renal-risk variants induce mitochondrial dysfunction. *J Am Soc Nephrol* 2017;28(4):1093-105.
50. Granado D, Müller D, Krausel V, Kruzel-Davila E, Schuberth C, Eschborn M, et al. Intracellular *APOL1* risk variants cause cytotoxicity accompanied by energy depletion. *J Am Soc Nephrol* 2017;28(11):3227-38.
51. Cheng D, Weckerle A, Yu Y, Ma L, Zhu X, Murea M, et al. Biogenesis and cytotoxicity of *APOL1* renal risk variant proteins in hepatocytes and hepatoma cells. *J Lipid Res* 2015;56(8):1583-93.
52. Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. *J Biol Chem* 2008;283(31):21540-9.
53. Hu C-AA, Klopfer EI, Ray PE. Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease. *FEBS Lett* 2012;586(7):947-55.
54. Beckerman P, Bi-Karchin J, Park ASD, Qiu C, Dummer PD, Soomro I, et al. Transgenic expression of human *APOL1* risk variants in podocytes induces kidney disease in mice. *Nat Med* 2017;23(4):429-38.





55. Hayek SS, Koh KH, Grams ME, Wei C, Ko Y-A, Li J, et al. A tripartite complex of suPAR, *APOL1* risk variants and $\alpha\text{v}\beta 3$ integrin on podocytes mediates chronic kidney disease. *Nat Med* 2017;23(8):945–53.
56. Cathelin D, Placier S, Ploug M, Verpont M-C, Vandermeersch S, Luque Y, et al. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. *J Am Soc Nephrol* 2014;25(8):1662–8.
57. Okamoto K, Tokunaga K, Doi K, Fujita T, Suzuki H, Katoh T, et al. Common variation in *GPC5* is associated with acquired nephrotic syndrome. *Nat Genet* 2011;43(5):459–63.
58. Limou S, Dummer PD, Nelson GW, Kopp JB, Winkler CA. *APOL1* toxin, innate immunity, and kidney injury. *Kidney Int* 2015;88(1):28–34.
59. Lee BT, Kumar V, Williams TA, Abdi R, Bernhardt A, Dyer C, et al. The *APOL1* genotype of African American kidney transplant recipients does not impact 5-year allograft survival. *Am J Transplant* 2012;12(7):1924–8.
60. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, et al. The *APOL1* gene and allograft survival after kidney transplantation. *Am J Transplant* 2011;11(5):1025–30.
61. Freedman BI, Julian BA, Pastan SO, Israni AK, Schladt D, Gautreaux MD, et al. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. *Am J Transplant* 2015;15(6):1615–22.
62. Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, et al. *APOL1* genotype and kidney transplantation outcomes from deceased African American donors. *Transplantation* 2016;100(1):194–202.
63. Zwang NA, Shetty A, Sustento-Reodica N, Gordon EJ, Leventhal J, Gallon L, et al. *APOL1*-associated end-stage renal disease in a living kidney transplant donor. *Am J Transplant* 2016;16(12):3568–72.
64. Doshi MD, Ortigosa-Goggins M, Garg AX, Li L, Poggio ED, Winkler CA, et al. *APOL1* genotype and renal function of black living donors. *J Am Soc Nephrol* 2018;29(4):1309–16.
65. Julian BA, Gaston RS, Brown WM, Reeves-Daniel AM, Israni AK, Schladt DP, et al. Effect of replacing race with apolipoprotein l1 genotype in calculation of kidney donor risk index. *Am J Transplant* 2017;17(6):1540–8.

66. Rao PS, Schaubel DE, Guidinger MK, Andreoni KA, Wolfe RA, Merion RM, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. *Transplantation* 2009;88(2):231–6.
67. Freedman BI, Moxey-Mims M. The APOL1 Long-Term Kidney Transplantation Outcomes Network-APOLLO. *Clin J Am Soc Nephrol* 2018;13(6):940–2.

Figure legends

Figure 1. APOL1, an example of balancing selection. **a:** African-Americans carrying two *APOL1* risk variants (recessive model) are at increased risk for non-diabetic chronic and end-stage kidney diseases (22,23,25-28); **b:** *APOL1* renal risk variants showed a signature of recent positive selection in West Africa by African trypanosomes, especially *T.b. rhodesiense* (22,31). Carriage of one *APOL1* allele is sufficient for protecting against trypanosome infection. However, the evolutive story might be more complex (see main text); **c:** Overall, *APOL1* alleles are a perfect example of balancing selection between chronic/end-stage kidney disease risk and trypanosomiasis protection. Individuals carrying only one *APOL1* allele present a fitness advantage compared to individuals carrying 0 or 2 risk alleles, as they are simultaneously protected from trypanosome infections and not at increased risk for chronic/end-stage kidney disease. The number of *APOL1* risk alleles is indicated under each individual. Zero risk allele: G0/G0 (or WT/WT); one risk allele: G0/G1 or G0/G2; two risk alleles: renal high-risk genotypes, G1/G1, G1/G2 or G2/G2. CKD, chronic kidney disease; ESKD, end-stage kidney disease.

Figure 2. APOL1-associated outcomes in kidney transplantation. Donor *APOL1* high-risk genotypes (and not recipient) were associated with a faster allograft failure (59-62) and with higher rates of post-donation end-stage kidney disease in living kidney donors (63,64). *APOL1* HR: *APOL1* high-risk genotypes; ESKD: end-stage kidney disease.



donor

recipient

